Also found in: Medical, Wikipedia.


Either of two neuropeptide hormones synthesized in the hypothalamus that regulate sleep and wakefulness and whose dysfunction causes narcolepsy. Also called hypocretin.

[Greek orexis, appetite (from the view that orexin stimulates appetite; see anorexia) + -in.]


a hormone that promotes wakefulness and stimulates the appetite
Mentioned in ?
References in periodicals archive ?
Key regions - Americas - APAC - EMEAKey Vendors - Eisai - Merck - Pfizer - Sanofi - TakedaOther prominent vendors - Astellas - Biocodex - Dainippon Sumitomo - ECR Pharmaceuticals (Valeant) - Fidia Farmaceutici - Flynn Pharma - Johnson & Johnson - Juste - MedaKey Market Driver - Unmet medical needs - For a full, detailed list, view our reportKey Market Challenge - Dominance of generic products - For a full, detailed list, view our reportKey Market Trend - Emerging drugs targeting orexin receptors - For a full, detailed list, view our reportKey Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be?
Among their research experiments include those that seek to "restore orexin signaling in the brains of narcoleptic mice and the new discovery of more histamine neurons in people with narcolepsy,'' according to Dr.
Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States.
The study, led by Stanford researchers, found that people with narcolepsy had cadres of immune T cells that target neurons making the peptide orexin (also called hypocretin), a neurotransmitter crucial for staying awake.
Belsomra is an orexin receptor antagonist and is the first approved drug of this type.
PHILADELPHIA -- An orexin receptor antagonist--the first drug to affect a neural system that promotes wakefulness--has proven safe and effective for up to 1 year in a pooled analysis of three phase III studies of patients with insomnia.
The scientists also found that the orexin neurons in the brains of injured mice were much less active than the same neurons in uninjured mice.
Scientists at the University of Cambridge compared actions of different nutrients on orexin cells.
Instead, opt for lean proteins like fish, which are less sensitive to orexin, a hormone that keeps you awake.
The aim of this study was to evaluate the expression of the orexin receptor in different prostate pathologies, including prostate adenocarcinoma, benign prostate hyperplasia and chronic prostatitis.
This can be especially beneficial in those with type II diabetes, since orexin improves insulin sensitivity and helps prevent an increase in body fat.
Scientists are developing Orexin A to reduce sleep without the feeling of edginess.